Substance,Type of TRV,TRV Value,Study Details,"Threshold/
Non-threshold
Endpoint",TRV Derivation Method,"Critical
Effect(s)","Carcinogenicity
Classification",Source
"Polychlorinated
biphenyls (PCBs)
(non dioxin-like
i.e., non-coplanar)","Oral TDI
(provisional)","1.0E-05
mg/kg -day
BW
(based on an
Aroclor
1254
mixture)","Study Type: chronic
Species: female rhesus monkeys
Mode of Administration: oral
(ingestion of capsules containing
Aroclor in a 1:1 glycerol/corn
1254
oil mixture)
Exposure Regime: 0, 0.005, 0.02, 0.04,
or 0.08 mg/kg -day
BW
Duration: 23 months and 55 months
(same group)
Uncertainty Factors: 300 (10 for
intraspecies variability, 3 for interspecies
variability, and 10 to extrapolate from
a LOAEL to a NOAEL)","LOAEL for Aroclor =
1254
0.005 mg/kg -day
BW","As per Baars et al., 2001,
TDI for
mixture of non dioxin-like
(i.e., non-coplanar PCBs)
=
50% of the TDI of Aroclor
1254
(based on chemical analysis
of seven ”indicator PCBs”
[PCB # 28, 52, 101, 118,
138, 153, and 180])
LOAEL Aroclor /UF
1254
= 1.7E-05 mg/kg -day
BW
(rounded to
2.0E-05 mg/kg -day)
BW
TDI Aroclor =
1254
2.0E-05 mg/kg -day ×
BW
50% =
1.0E-05 mg/kg -day
BW","Immunotoxicity
(decreased
antibody response)","CEPA:
not classified
IARC:
not classified
US EPA IRIS:
not classified","WHO, 2003
(based on
Tryphonas et al.,
1989, 1991),
and
Baars et al., 2001"
"Polychlorinated
biphenyls (PCBs)2
(dioxin-like,
i.e. coplanar)",Oral TDI,"2.3E-09 TEQ
mg/kg -day
BW","See PCDDs/PCDFs for study details.
Dioxin-like (i.e., coplanar) PCBs should be evaluated with PCDDs/PCDFs, using appropriate TEFs (see Table 4).",,,,"CEPA:
not classified
IARC: Group 1;
dioxin-like
(i.e., coplanar)
PCBs classified
as carcinogenic
to humans
(IARC, 2016)
US EPA IRIS:
Group B2
probably
carcinogenic
to humans
(US EPA, 1996)","See PCDDs/
PCDFs for source
information."
